The Scale of an Underdiagnosed Condition

Primary hyperaldosteronism (PA) is the leading form of endocrine hypertension, estimated to affect 5–13% of hypertensive patients and up to 29% of those with resistant hypertension — yet it remains substantially underdiagnosed in routine clinical practice. The condition arises from autonomous aldosterone overproduction by the adrenal zona glomerulosa, independent of the renin-angiotensin system, and drives a cardiovascular risk burden that exceeds that of blood pressure-matched essential hypertension.

Two subtypes dominate the clinical picture. Unilateral aldosterone-producing adenoma (APA) accounts for approximately 40% of cases and is potentially curable with surgery. Bilateral idiopathic hyperaldosteronism (IHA) accounts for the remaining 60% and requires long-term pharmacological management. This subtype split is the central diagnostic challenge that has driven decades of innovation in both imaging and biomarker research.

At the genetic level, somatic mutations in KCNJ5 (Kir3.4 potassium channel), CACNA1D (CaV1.3 calcium channel), ATP1A1, ATP2B3, CACNA1H, CLCN2, and CTNNB1 are collectively present in more than 90% of APAs. These mutations converge on a common mechanism: cell membrane depolarisation, voltage-gated calcium channel activation, intracellular calcium elevation, and downstream CYP11B2 transcriptional upregulation. According to WHO classifications, secondary hypertension from endocrine causes represents a distinct and treatable category — making accurate subtyping a clinical priority.

CYP11B2 Inhibitors: From First-Generation Failures to Selective Candidates

The aldosterone synthase inhibitor class has progressed through two distinct generations, with a third compound now at patent stage — each iteration addressing the selectivity liability that defined the class’s central challenge. CYP11B2 shares 93% amino acid homology with CYP11B1, making selectivity over cortisol synthesis the defining technical hurdle.

LCI699: The First Clinical Signal and Its Limitation

LCI699 was the first aldosterone synthase inhibitor to enter clinical investigation, demonstrating competitive blood pressure reduction at lower doses. However, at higher doses it caused off-target inhibition of CYP11B1 (11β-hydroxylase), triggering compensatory hypothalamic-pituitary-adrenal axis upregulation. This mechanistic interference limited its therapeutic selectivity and constrained dose escalation in essential, uncontrolled, resistant, and secondary hypertension cohorts.

RO6836191: A Selectivity Benchmark

Developed at Roche in collaboration with the William Harvey Research Institute, RO6836191 represents the second generation of CYP11B2 inhibition. It is reported as a potent competitive inhibitor with a Ki of 13 nmol/L and greater than 100-fold in vitro selectivity over CYP11B1. In cynomolgus monkeys challenged with synthetic ACTH, single doses inhibited aldosterone synthesis without affecting the ACTH-induced cortisol rise — a critical selectivity benchmark that LCI699 could not achieve.

(R)-Compound 1 (CinCor Pharma): The Current Patent Frontier

The most recent patent-stage signal in this dataset comes from CinCor Pharma’s 2024 Australian patent filing, which describes methods of inhibiting human aldosterone synthase and treating both hypertension and primary aldosteronism using (R)-Compound 1. The compound is characterised as rapidly absorbed with a long half-life suitable for once-daily dosing. The patent filing presents human pharmacokinetic data from days 1 and 10 of dosing and includes an ACTH-stimulation challenge dataset with multiple dose groups — a data structure consistent with Phase 1/2 clinical trial evidence.

“RO6836191 inhibited aldosterone synthesis without affecting the ACTH-induced cortisol rise in cynomolgus monkeys — a critical selectivity benchmark that defined the second generation of CYP11B2 inhibitors.”

[18F]AldoView: CYP11B2 as an Imaging Target

Parallel to therapeutic inhibitor development, University College London developed [18F]AldoView as the first highly selective CYP11B2 PET tracer. In ex vivo adrenal tissue from PA patients, the tracer demonstrated avid binding to adenomas, binding patterns consistent with aldosterone-producing cell clusters (APCCs), and concordance with anti-hCYP11B2 immunostaining. This positions [18F]AldoView as a potential non-invasive alternative to adrenal vein sampling for surgical lateralisation — a significant procedural implication if validated in vivo.

MRA Therapy and Surgical Cure: What the Outcomes Data Show

Mineralocorticoid receptor antagonists (MRAs) — spironolactone, eplerenone, and amiloride — remain the established pharmacological standard of care for bilateral PA and for patients who are not surgical candidates. Long-term outcomes data provide a nuanced picture of both their efficacy and their limitations relative to surgical intervention.

In a retrospective cohort of 155 long-term PA patients on MRA therapy, 57.4% achieved blood pressure below 140/90 mmHg, 90.1% achieved normokalemia, and 63.2% achieved renin above 1 ng/mL/h. However, side effects were experienced by 52.3% of patients — a tolerability signal that underscores the clinical rationale for surgical cure where feasible. The novel selective mineralocorticoid receptor modulator AZD9977 (AstraZeneca) shows a dissociated pharmacological profile in preclinical data, demonstrating organ-protective effects without sodium excretion perturbation when tested against aldosterone, suggesting potential for an improved tolerability profile versus conventional MRAs.

Laparoscopic adrenalectomy is the guideline-endorsed curative intervention for unilateral PA, offering biochemical cure of aldosterone excess and hypokalemia alongside mitigation of long-term cardiovascular risk that exceeds what MRA therapy alone can achieve. However, hypertension resolution after adrenalectomy is not universal. A Korean single-centre cohort of 27 APA patients reported that 59.3% achieved complete resolution of hypertension after adrenalectomy, while 25.9% showed improvement — leaving a meaningful proportion with residual hypertension. The Aldosteronoma Resolution Score (ARS) has been identified as a tool to predict surgical cure rates.

Persistent hypertension post-adrenalectomy has a molecular correlate: Nox2 and p22phox NADPH oxidase overexpression in APA tissue implicates reactive oxygen species cascades as a mechanism for residual hypertension after surgical cure, according to research from Sun Yat-sen University. This finding opens a potential pharmacological target for the post-surgical residual hypertension population — a gap that neither MRAs nor CYP11B2 inhibitors currently address directly. Regulatory frameworks from agencies such as EMA and FDA have not yet approved a dedicated CYP11B2 inhibitor, reinforcing the clinical gap that the pipeline is working to fill.

Beyond Adrenal Vein Sampling: Non-Invasive Localisation Strategies

Adrenal vein sampling (AVS) remains the reference standard for distinguishing unilateral from bilateral PA — a distinction that determines whether a patient is offered potentially curative surgery. However, AVS is technically demanding, available only at specialised centres, and carries procedural risk. The field is actively developing non-invasive alternatives across three distinct modalities.

CYP11B2-Targeted PET Imaging

The [18F]AldoView tracer developed at University College London represents the most direct non-invasive challenge to AVS. By targeting CYP11B2 directly, the tracer demonstrated avid binding to adenomas and concordance with immunostaining in ex vivo human adrenal tissue — providing a translational bridge from preclinical validation to potential in vivo clinical imaging. If validated in prospective in vivo studies, [18F]AldoView could guide surgical lateralisation without catheterisation.

Liquid Biopsy-Type Biomarkers

Urinary extracellular vesicle NCC/pNCC (sodium chloride cotransporter) expression has been proposed by researchers at Shanghai Jiao Tong University as a biomarker for PA subtype differentiation and AVS candidate selection. Separately, serum alpha-1-acid glycoprotein-1 and urinary EV miR-21-5p have been evaluated as novel PA biomarkers. These signals collectively suggest the field is exploring liquid biopsy-type approaches to either replace or triage AVS — analogous to developments in oncology where liquid biopsy has reduced the need for invasive tissue sampling.

Plasma Ratio Diagnostics

Attoquant Diagnostics GmbH holds an active 2019 EP patent claiming a diagnostic method based on the plasma angiotensin II/aldosterone ratio — a quantitative, blood-based approach to PA diagnosis that represents a clinically applicable tool with active commercial IP. This is the only diagnostic-focused patent in the dataset and signals commercial interest in non-invasive PA subtyping. Research published through NEJM and guidelines from the Endocrine Society continue to shape the diagnostic framework within which these innovations will be evaluated.

Emerging Molecular Targets and Combination Directions

Beyond the established CYP11B2 and mineralocorticoid receptor axes, the PA pipeline contains several experimental molecular targets that could define the next therapeutic generation — particularly for patients who fail or are intolerant of current options.

CaV1.3 (CACNA1D) Selective Blockade

CACNA1D mutations are the leading somatic driver in aldosterone-producing cell clusters (APCCs) and are also frequently found in zona glomerulosa-like APAs. “Compound 8,” a novel CaV1.3 antagonist characterised at Queen Mary University London, reduced aldosterone production in both wild-type and mutant CaV1.3-transfected H295R cells and in primary human adrenal cells, with superior selectivity over vascular CaV1.2 compared to nifedipine. This selectivity profile addresses a key concern with non-selective calcium channel blockers — cardiovascular off-target effects.

Calcineurin/NFATC4 Pathway

Research from the Swiss National Centre for Competence in Research Kidney.CH (2023) identified calcineurin (protein phosphatase 3) as a regulator of CYP11B2 via dephosphorylation of NFATC4. Tacrolimus-mediated calcineurin inhibition abolished potassium-stimulated CYP11B2 expression in NCI-H295R cells and in ex vivo human adrenal tissue. This raises the possibility that selective NFATC4 modulators — or repurposed calcineurin inhibitors — could suppress CYP11B2 transcriptionally, downstream of calcium signalling and upstream of enzyme activity.

ACAT Inhibition: A Post-Depolarisation Mechanism

YM750, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor studied at Tohoku University, was found to suppress KCl-stimulated CYP11B2 expression and aldosterone secretion in adrenocortical cells without inhibiting calcium influx. This post-depolarisation mechanism of action is distinct from both calcium channel blockers and direct CYP11B2 inhibitors, suggesting potential for combination approaches that target multiple nodes of the depolarisation-aldosterone axis simultaneously.

CYP11B2/Adrenodoxin Interface

Structural biology work at the University of Michigan systematically characterised the adrenodoxin interaction with CYP11B2, revealing allosteric modulation in addition to electron transfer. Local adrenodoxin concentration was found to modulate substrate binding in CYP11B2 — identifying the CYP11B2/adrenodoxin interface as a potential drug target distinct from the enzyme’s active site. This allosteric approach could offer selectivity advantages over active-site inhibitors given the homology challenge with CYP11B1.

“Somatic mutations in KCNJ5, CACNA1D, ATP1A1, ATP2B3, CACNA1H, CLCN2, and CTNNB1 are collectively present in more than 90% of aldosterone-producing adenomas — all converging on cell membrane depolarisation and downstream CYP11B2 upregulation.”

Assignee Landscape: Academic Dominance, Nascent Commercial IP

The dataset reveals a striking asymmetry: more than 50 academic papers versus only three patent records, indicating that commercial IP activity is nascent relative to the mature research base. The three active commercial assignees are CinCor Pharma (2024 AU patent, (R)-Compound 1 methods), Attoquant Diagnostics GmbH (2019 EP patent, plasma ratio diagnostic), and — historically — Merrell Dow Pharmaceuticals (1992, now inactive). Academic institutions driving the scientific base include Queen Mary University of London, University College London, University of Michigan, Tohoku University, Berlin Institute of Health at Charité, and the Taiwan National Health Research Institutes. The commercial IP gap relative to the research base represents both a risk and an opportunity for pharmaceutical developers tracking this space through platforms such as PatSnap‘s patent analytics tools.